GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alder BioPharmaceuticals Inc (NAS:ALDR) » Definitions » ROA %

Alder BioPharmaceuticals (Alder BioPharmaceuticals) ROA % : -47.89% (As of Jun. 2019)


View and export this data going back to 2014. Start your Free Trial

What is Alder BioPharmaceuticals ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Alder BioPharmaceuticals's annualized Net Income for the quarter that ended in Jun. 2019 was $-233.64 Mil. Alder BioPharmaceuticals's average Total Assets over the quarter that ended in Jun. 2019 was $487.87 Mil. Therefore, Alder BioPharmaceuticals's annualized ROA % for the quarter that ended in Jun. 2019 was -47.89%.

The historical rank and industry rank for Alder BioPharmaceuticals's ROA % or its related term are showing as below:

ALDR's ROA % is not ranked *
in the Biotechnology industry.
Industry Median: -35.15
* Ranked among companies with meaningful ROA % only.

Alder BioPharmaceuticals ROA % Historical Data

The historical data trend for Alder BioPharmaceuticals's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alder BioPharmaceuticals ROA % Chart

Alder BioPharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
ROA %
Get a 7-Day Free Trial 19.56 -36.81 -38.62 -81.11 -81.28

Alder BioPharmaceuticals Quarterly Data
Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.67 -46.63 -69.42 -100.43 -47.89

Competitive Comparison of Alder BioPharmaceuticals's ROA %

For the Biotechnology subindustry, Alder BioPharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alder BioPharmaceuticals's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alder BioPharmaceuticals's ROA % distribution charts can be found below:

* The bar in red indicates where Alder BioPharmaceuticals's ROA % falls into.



Alder BioPharmaceuticals ROA % Calculation

Alder BioPharmaceuticals's annualized ROA % for the fiscal year that ended in Dec. 2018 is calculated as:

ROA %=Net Income (A: Dec. 2018 )/( (Total Assets (A: Dec. 2017 )+Total Assets (A: Dec. 2018 ))/ count )
=-296.429/( (303.136+426.239)/ 2 )
=-296.429/364.6875
=-81.28 %

Alder BioPharmaceuticals's annualized ROA % for the quarter that ended in Jun. 2019 is calculated as:

ROA %=Net Income (Q: Jun. 2019 )/( (Total Assets (Q: Mar. 2019 )+Total Assets (Q: Jun. 2019 ))/ count )
=-233.644/( (513.168+462.567)/ 2 )
=-233.644/487.8675
=-47.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2019) net income data. ROA % is displayed in the 30-year financial page.


Alder BioPharmaceuticals  (NAS:ALDR) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2019 )
=Net Income/Total Assets
=-233.644/487.8675
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-233.644 / 0)*(0 / 487.8675)
=Net Margin %*Asset Turnover
=N/A %*0
=-47.89 %

Note: The Net Income data used here is four times the quarterly (Jun. 2019) net income data. The Revenue data used here is four times the quarterly (Jun. 2019) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Alder BioPharmaceuticals ROA % Related Terms

Thank you for viewing the detailed overview of Alder BioPharmaceuticals's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alder BioPharmaceuticals (Alder BioPharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
11804 North Creek Parkway South, Bothell, WA, USA, 98011
Alder BioPharmaceuticals is a biotechnology company that seeks to discover, develop, and commercialize therapeutic antibodies. The company's antibody platform seeks to maximize efficacy, as well as speed of onset and durability of therapeutic response. Alder's product pipeline addresses diseases where patients have limited medical options or where current medical options may not meet the needs of a substantial number of patients. The company operates in two geographic regions: the United States and Australia. The vast majority of the Alder's assets are located in the United States, where the vast majority of its revenue is also generated.
Executives
Paul Rutherford Carter director SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF
H Lundbeck A S 10 percent owner 9 OTTILIAVEJ DK 2500 VALBY, COPENHAGEN, DENMARK G7 00000
Clay B Siegall director 21823 30TH DR SE, BOTHELL WA 98021
Paul Streck officer: Chief Medical Officer 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Wendy L Yarno director
Carlos Campoy officer: Chief Financial Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Robert Azelby director, officer: President and CEO 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Heather Preston director C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102
Jeremy Green director 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc director ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Paul B Cleveland director C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Alan Bruce Montgomery director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Mark James Litton officer: Chief Business Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Eric G Carter officer: Interim Chief Medical Officer C/O KING PHARMACEUTICALS, INC., 501 FIFTH STREET, BRISTOL TN 37620

Alder BioPharmaceuticals (Alder BioPharmaceuticals) Headlines

From GuruFocus